Bayer and Pfizer Join Hands to fight Obesity and Diabetes

Pfizer Inc. received exclusive worldwide rights to a class of Bayer Pharmaceuticals Corp. compounds that could lead to treatments for diabetes and obesity.

The class of compounds, called DGAT-1 inhibitors, modify lipid metabolism. The lead compound in the group is a potential treatment for obesity, type 2 diabetes and other related disorders. The compound is still in Phase I clinical development.

Link [www.marketwatch.com/News/Story/Story.aspx?guid=%7B40CB471E-5D90-492E-9E2F-9ECCDF2378C4%7D&siteid=google]

Filed under Diabetes, Obesity | Comment Below

Related?

Leave a Reply


Protected by Comment Guard Pro